Beth A. Hellerstedt

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Lee Schwartzberg, Michael Danso et al. · Journal of Clinical Oncology · 2014 · 299 citations · Full text

Gene Pathways Associated With Prognosis and Chemotherapy Sensitivity in Molecular Subtypes of Breast Cancer

Takayuki Iwamoto, Giampaolo Bianchini, Daniel J. Booser et al. · JNCI Journal of the National Cancer Institute · 2010 · 230 citations

Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Gregory A. Yanik, Beth A. Hellerstedt, Joseph R. Custer et al. · Biology of Blood and Marrow Transplantation · 2002 · 126 citations · Full text

Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers

Libero Santarpia, Yuan Qi, Katherine Stemke‐Hale et al. · Breast Cancer Research and Treatment · 2012 · 110 citations · Full text

Breast Oncology, Oncology, Engineering +14